** Clarity Pharmaceuticals CU6.AX rises as much as 5.6% to A$7.6, its highest since Oct. 9
** Co signs agreement with U.S.-based firm Nucleus Radiopharma to produce their Cu-SAR-bisPSMA drug for the imaging and treatment of prostate cancer
** Says agreement to expand production anticipating recruitment demand for drug's phase II and phase III trials
** Stock posts largest intraday pct gain since Oct. 25
** YTD, CU6 has nearly tripled
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。